Cullinan reports Phase 1 CLN-619 data: 1 CR, 2 PRs in solid tumors; expansion in endometrial/cervical cancers

Cullinan Therapeutics, Inc.

CLN-619 monotherapy showed 1 complete response (parotid gland cancer) and 2 unconfirmed partial responses (endometrial cancer) in heavily pre-treated patients.
54% of patients had prior checkpoint inhibitor therapy; responses observed in patients who progressed on prior CPI.
No dose-limiting toxicities across 0.1-10 mg/kg doses; infusion reactions Grade 1/2 only with pre-medication.
Based on gynecologic activity, company will initiate monotherapy expansion cohorts in endometrial and cervical cancers.
Phase 1 trial continues enrolling monotherapy and combination (with pembrolizumab) arms; future results to be shared.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.